- /
- Supported exchanges
- / US
- / MGX.NASDAQ
Metagenomi, Inc. Common Stock (MGX NASDAQ) stock market data APIs
Metagenomi, Inc. Common Stock Financial Data Overview
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Metagenomi, Inc. Common Stock (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Metagenomi, Inc. Common Stock data using free add-ons & libraries
Get Metagenomi, Inc. Common Stock Fundamental Data
Metagenomi, Inc. Common Stock Fundamental data includes:
- Net Revenue: 30 913 K
- EBITDA: -86 791 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-11
- EPS/Forecast: -0.8
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Metagenomi, Inc. Common Stock News
New
After-Hours Gainers: Exicure Tops List With 72% Jump, Wave Life And Assembly Biosciences Advance
(RTTNews) - Biotechnology stocks saw notable movement in after-hours trading on Monday, with several companies posting strong gains. Below is a structured look at the key movers and the developments d...
Trainium3 UltraServers Now Available: Enabling Customers to Train and Deploy AI Models Faster at Lower Cost
Amazon EC2 Trn3 UltraServers powered by AWS's first 3nm AI chip help organizations of all sizes run their most ambitious AI training and inference workloads LAS VEGAS, December 02, 2025--(BUSINESS WI...
Amazon Launches New AI Chip While Teasing Future Tech Collaboration With Nvidia
Amazon stock was higher after the tech giant announced its Trainium3 AI chip is now available for customers of AWS. Continue Reading
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
Metagenomi, Inc. EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologi...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.